1932

Abstract

Apoptosis is critical for embryonic development, tissue homeostasis, and the removal of infected or otherwise dangerous cells. It is controlled by three subgroups of the BCL-2 protein family—the BH3-only proteins that initiate cell death; the effectors of cell killing, BAX and BAK; and the antiapoptotic guardians, including MCL-1 and BCL-2. Defects in apoptosis can promote tumorigenesis and render malignant cells refractory to anticancer therapeutics. Activation of cell death by inhibiting antiapoptotic BCL-2 family members has emerged as an attractive strategy for cancer therapy, with the BCL-2 inhibitor venetoclax leading the way. Large-scale cancer genome analyses have revealed frequent amplification of the locus encoding antiapoptotic in human cancers, and functional studies have shown that MCL-1 is essential for the sustained survival and expansion of many types of tumor cells. Structural analysis and medicinal chemistry have led to the development of three distinct small-molecule inhibitors of MCL-1 that are currently undergoing clinical testing.

[Erratum, Closure]

An erratum has been published for this article:
Erratum: Toward Targeting Antiapoptotic MCL-1 for Cancer Therapy
Loading

Article metrics loading...

/content/journals/10.1146/annurev-cancerbio-030419-033510
2020-03-04
2024-06-22
Loading full text...

Full text loading...

/deliver/fulltext/cancerbio/4/1/annurev-cancerbio-030419-033510.html?itemId=/content/journals/10.1146/annurev-cancerbio-030419-033510&mimeType=html&fmt=ahah

Literature Cited

  1. Akgul C, Turner PC, White MR, Edwards SW 2000. Functional analysis of the human MCL-1 gene. Cell Mol. Life Sci. 57:684–91
    [Google Scholar]
  2. Arbour N, Vanderluit JL, Le Grand JN, Jahani-Asl A, Ruzhynsky VA et al. 2008. Mcl-1 is a key regulator of apoptosis during CNS development and after DNA damage. J. Neurosci. 28:6068–78
    [Google Scholar]
  3. Beroukhim R, Mermel C, Porter D, Wei G, Raychaudhuri S et al. 2010. The landscape of somatic copy-number alteration across human cancers. Nature 463:899–905
    [Google Scholar]
  4. Bouillet P, Cory S, Zhang L-C, Strasser A, Adams JM 2001. Degenerative disorders caused by Bcl-2 deficiency are prevented by loss of its BH3-only antagonist Bim. Dev. Cell 1:645–53
    [Google Scholar]
  5. Bouillet P, Metcalf D, Huang DC, Tarlinton DM, Kay TW et al. 1999. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 286:1735–38
    [Google Scholar]
  6. Brennan MS, Chang C, Tai L, Lessene G, Strasser A et al. 2018. Humanized Mcl-1 mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical use. Blood 132:1573–83
    [Google Scholar]
  7. Brinkmann K, Grabow S, Hyland CD, Teh CE, Alexander WS et al. 2017. The combination of reduced MCL-1 and standard chemotherapeutics is tolerable in mice. Cell Death Differ 24:2032–43
    [Google Scholar]
  8. Caenepeel S, Brown SP, Belmontes B, Moody G, Keegan KS et al. 2018. AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies. Cancer Discov 8:1582–97
    [Google Scholar]
  9. Campbell KJ, Bath ML, Turner ML, Vandenberg CJ, Bouillet P et al. 2010. Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance. Blood 116:3197–207
    [Google Scholar]
  10. Campbell KJ, Dhayade S, Ferrari N, Sims AH, Johnson E et al. 2018. MCL-1 is a prognostic indicator and drug target in breast cancer. Cell Death Dis 9:19
    [Google Scholar]
  11. Campbell KJ, Tait SWG. 2018. Targeting BCL-2 regulated apoptosis in cancer. Open Biol 8:180002
    [Google Scholar]
  12. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO et al. 2012. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401–4
    [Google Scholar]
  13. Chao J-R, Wang J-M, Lee S-F, Peng H-W, Lin Y-H et al. 1998. mcl-1 is an immediate-early gene activated by the granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling pathway and is one component of the GM-CSF viability response. Mol. Cell. Biol. 18:4883–98
    [Google Scholar]
  14. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI et al. 2005. Differential targeting of pro-survival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol. Cell 17:393–403
    [Google Scholar]
  15. Cragg MS, Harris C, Strasser A, Scott CL 2009. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat. Rev. Cancer 9:321–26
    [Google Scholar]
  16. Czabotar PE, Lessene G, Strasser A, Adams JM 2014. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat. Rev. Mol. Cell Biol. 15:49–63
    [Google Scholar]
  17. Delbridge AR, Grabow S, Bouillet P, Adams JM, Strasser A 2015. Functional antagonism between pro-apoptotic BIM and anti-apoptotic BCL-XL in MYC-induced lymphomagenesis. Oncogene 34:1872–76
    [Google Scholar]
  18. Ding Q, He X, Hsu JM, Xia W, Chen CT et al. 2007. Degradation of Mcl-1 by β-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol. Cell. Biol. 27:4006–17
    [Google Scholar]
  19. Friberg A, Vigil D, Zhao B, Daniels RN, Burke JP et al. 2013. Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design. J. Med. Chem. 56:15–30
    [Google Scholar]
  20. Glaser S, Lee EF, Trounson E, Bouillet P, Wei A et al. 2012. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev 26:120–25
    [Google Scholar]
  21. Gong J, Zhang JP, Li B, Zeng C, You K et al. 2013. MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R. Oncogene 32:3071–79
    [Google Scholar]
  22. Gong JN, Khong T, Segal D, Yao Y, Riffkin CD et al. 2016. Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. Blood 128:1834–44
    [Google Scholar]
  23. Grabow S, Delbridge AR, Aubrey BJ, Vandenberg CJ, Strasser A 2016. Loss of a single Mcl-1 allele inhibits MYC-driven lymphomagenesis by sensitizing pro-B cells to apoptosis. Cell Rep 14:2337–47
    [Google Scholar]
  24. Grabow S, Delbridge AR, Valente LJ, Strasser A 2014. MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice. Blood 124:3939–46
    [Google Scholar]
  25. Grabow S, Kueh AJ, Ke F, Vanyai HK, Sheikh BN et al. 2018. Subtle changes in the levels of BCL-2 proteins cause severe craniofacial abnormalities. Cell Rep 24:3285–95.e4
    [Google Scholar]
  26. Green DR. 2019. The coming decade of cell death research: five riddles. Cell 177:1094–107
    [Google Scholar]
  27. Hikita H, Takehara T, Shimizu S, Kodama T, Li W et al. 2009. Mcl-1 and Bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver. Hepatology 50:1217–26
    [Google Scholar]
  28. Huang DCS, Strasser A. 2000. BH3-only proteins—essential initiators of apoptotic cell death. Cell 103:839–42
    [Google Scholar]
  29. Huang HM, Huang CJ, Yen JJ 2000. Mcl-1 is a common target of stem cell factor and interleukin-5 for apoptosis prevention activity via MEK/MAPK and PI-3K/Akt pathways. Blood 96:1764–71
    [Google Scholar]
  30. Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A et al. 2011. SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 471:104–9
    [Google Scholar]
  31. Jeffers JR, Parganas E, Lee Y, Yang C, Wang J et al. 2003. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 4:321–28
    [Google Scholar]
  32. Ke FFS, Vanyai HK, Cowan AD, Delbridge ARD, Whitehead L et al. 2018. Embryogenesis and adult life in the absence of intrinsic apoptosis effectors BAX, BAK, and BOK. Cell 173:1217–30.e17
    [Google Scholar]
  33. Kelly GL, Grabow S, Glaser SP, Fitzsimmons L, Aubrey BJ et al. 2014. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev 28:58–70
    [Google Scholar]
  34. Kelly PN, Grabow S, Delbridge ARD, Strasser A, Adams JM 2011. Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice. Blood 118:6380–86
    [Google Scholar]
  35. Kelly PN, Puthalakath H, Adams JM, Strasser A 2007. Endogenous bcl-2 is not required for the development of Eμ-myc-induced B-cell lymphoma. Blood 109:4907–13
    [Google Scholar]
  36. Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L et al. 2016. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov 6:1106–17
    [Google Scholar]
  37. Koss B, Morrison J, Perciavalle RM, Singh H, Rehg JE et al. 2013. Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia. Blood 122:1587–98
    [Google Scholar]
  38. Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL et al. 2016. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 538:477–82
    [Google Scholar]
  39. Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P et al. 2006. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. PNAS 103:14907–12
    [Google Scholar]
  40. Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA et al. 2005. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol. Cell 17:525–35
    [Google Scholar]
  41. Le Gouill S, Podar K, Amiot M, Hideshima T, Chauhan D et al. 2004. VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. Blood 104:2886–92
    [Google Scholar]
  42. Lee EF, Harris TJ, Tran S, Evangelista M, Arulananda S et al. 2019. BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. Cell Death Dis 10:342
    [Google Scholar]
  43. Letai AG. 2008. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat. Rev. Cancer 8:121–32
    [Google Scholar]
  44. Leverson JD, Zhang H, Chen J, Tahir SK, Phillips DC et al. 2015. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis 6:e1590
    [Google Scholar]
  45. Lindsten T, Ross AJ, King A, Zong W, Rathmell JC et al. 2000. The combined functions of proapoptotic Bcl-2 family members Bak and Bax are essential for normal development of multiple tissues. Mol. Cell 6:1389–99
    [Google Scholar]
  46. Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA et al. 2007. Programmed anuclear cell death delimits platelet life span. Cell 128:1173–86
    [Google Scholar]
  47. Merino D, Kelly GL, Lessene G, Wei AH, Roberts AW, Strasser A 2018. BH3-mimetic drugs: blazing the trail for new cancer medicines. Cancer Cell 34:879–91
    [Google Scholar]
  48. Motoyama N, Wang F, Roth KA, Sawa H, Nakayama K et al. 1995. Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science 267:1506–10
    [Google Scholar]
  49. Mott JL, Kobayashi S, Bronk SF, Gores GJ 2007. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 26:6133–40
    [Google Scholar]
  50. Moujalled DM, Pomilio G, Ghiurau C, Ivey A, Salmon J et al. 2019. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. Leukemia 33:4905–17
    [Google Scholar]
  51. Nangia V, Siddiqui FM, Caenepeel S, Timonina D, Bilton SJ et al. 2018. Exploiting MCL1 dependency with combination MEK + MCL1 inhibitors leads to induction of apoptosis and tumor regression in KRAS-mutant non–small cell lung cancer. Cancer Discov 8:1598–613
    [Google Scholar]
  52. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ et al. 2005. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677–81
    [Google Scholar]
  53. Opferman JT, Iwasaki H, Ong CC, Suh H, Mizuno S et al. 2005. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 307:1101–4
    [Google Scholar]
  54. Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ 2003. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 426:671–76
    [Google Scholar]
  55. Pan R, Hogdal LJ, Benito JM, Bucci D, Han L et al. 2014. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov 4:362–75
    [Google Scholar]
  56. Papatzimas JW, Gorobets E, Maity R, Muniyat MI, MacCallum JL et al. 2019. From inhibition to degradation: targeting the antiapoptotic protein myeloid cell leukemia 1 (MCL1). J. Med. Chem. 62:5522–40
    [Google Scholar]
  57. Peperzak V, Vikstrom I, Walker J, Glaser SP, LePage M et al. 2013. Mcl-1 is essential for the survival of plasma cells. Nat. Immunol. 14:290–97
    [Google Scholar]
  58. Perciavalle RM, Stewart DP, Koss B, Lynch J, Milasta S et al. 2012. Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat. Cell Biol. 14:575–83
    [Google Scholar]
  59. Print CG, Loveland KL, Gibson L, Meehan T, Stylianou A et al. 1998. Apoptosis regulator Bcl-w is essential for spermatogenesis but appears otherwise redundant. PNAS 95:12424–31
    [Google Scholar]
  60. Puthalakath H, O'Reilly LA, Gunn P, Lee L, Kelly PN et al. 2007. ER stress triggers apoptosis by activating BH3-only protein Bim. Cell 129:1337–49
    [Google Scholar]
  61. Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H et al. 1997. Somatic frameshift mutations in the bax gene in colon cancers of the microsatellite mutator phenotype. Science 275:967–69
    [Google Scholar]
  62. Ramsey HE, Fischer MA, Lee T, Gorska AE, Arrate MP et al. 2018. A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia. Cancer Discov 8:1566–81
    [Google Scholar]
  63. Rinkenberger JL, Horning S, Klocke B, Roth K, Korsmeyer SJ 2000. Mcl-1 deficiency results in peri-implantation embryonic lethality. Genes Dev 14:23–27
    [Google Scholar]
  64. Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD et al. 2016. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 374:311–22
    [Google Scholar]
  65. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ et al. 2012. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J. Clin. Oncol. 30:488–96
    [Google Scholar]
  66. Schenk RL, Tuzlak S, Carrington EM, Zhan Y, Heinzel S et al. 2017. Characterisation of mice lacking all functional isoforms of the pro-survival BCL-2 family member A1 reveals minor defects in the haematopoietic compartment. Cell Death Differ 24:534–45
    [Google Scholar]
  67. Schwickart M, Huang X, Lill JR, Liu J, Ferrando R et al. 2010. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 463:103–7
    [Google Scholar]
  68. Singh R, Letai A, Sarosiek K 2019. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat. Rev. Mol. Cell Biol. 20:175–93
    [Google Scholar]
  69. Soucek L, Evan GI. 2010. The ups and downs of Myc biology. Curr. Opin. Genet. Dev. 20:91–95
    [Google Scholar]
  70. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND et al. 2013. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19:202–8
    [Google Scholar]
  71. Spinner S, Crispatzu G, Yi JH, Munkhbaatar E, Mayer P et al. 2016. Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance. Leukemia 30:1520–30
    [Google Scholar]
  72. Strasser A, Harris AW, Bath ML, Cory S 1990. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348:331–33
    [Google Scholar]
  73. Strasser A, Harris AW, Cory S 1991. Bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. Cell 67:889–99
    [Google Scholar]
  74. Strasser A, O'Connor L, Dixit VM 2000. Apoptosis signaling. Annu. Rev. Biochem. 69:217–45
    [Google Scholar]
  75. Tagawa H, Karnan S, Suzuki R, Matsuo K, Zhang X et al. 2005. Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. . Oncogene 24:1348–58
    [Google Scholar]
  76. Thomas LW, Lam C, Edwards SW 2010. Mcl-1; the molecular regulation of protein function. FEBS Lett 584:2981–89
    [Google Scholar]
  77. Thomas RL, Roberts DJ, Kubli DA, Lee Y, Quinsay MN et al. 2013. Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. Genes Dev 27:1365–77
    [Google Scholar]
  78. Tron AE, Belmonte MA, Adam A, Aquila BM, Boise LH et al. 2018. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat. Commun. 9:5341
    [Google Scholar]
  79. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM 1984. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226:1097–99
    [Google Scholar]
  80. Vaux DL, Cory S, Adams JM 1988. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335:440–42
    [Google Scholar]
  81. Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ 1993. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 75:229–40
    [Google Scholar]
  82. Vikstrom IB, Carotta S, Luethje K, Peperzak V, Jost PJ et al. 2010. Mcl-1 is essential for germinal center formation and B cell memory. Science 330:1095–99
    [Google Scholar]
  83. Vikstrom IB, Slomp A, Carrington EM, Moesbergen LM, Chang C et al. 2016. MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL. Cell Death Dis 7:e2345
    [Google Scholar]
  84. Villanova L, Careccia S, De Maria R, Fiori ME 2018. Micro-economics of apoptosis in cancer: ncRNAs modulation of BCL-2 family members. Int. J. Mol. Sci. 19:958
    [Google Scholar]
  85. Villunger A, Michalak EM, Coultas L, Mullauer F, Bock G et al. 2003. p53- and drug-induced apoptotic responses mediated by BH3-only proteins Puma and Noxa. Science 302:1036–38
    [Google Scholar]
  86. Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ et al. 2012. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell 151:344–55
    [Google Scholar]
  87. Wagner KU, Claudio E, Rucker EB 3rd, Riedlinger G, Broussard C et al. 2000. Conditional deletion of the Bcl-x gene from erythroid cells results in hemolytic anemia and profound splenomegaly. Development 127:4949–58
    [Google Scholar]
  88. Wang JM, Lai MZ, Yang-Yen HF 2003. Interleukin-3 stimulation of mcl-1 gene transcription involves activation of the PU.1 transcription factor through a p38 mitogen-activated protein kinase-dependent pathway. Mol. Cell. Biol. 23:1896–909
    [Google Scholar]
  89. Wang X, Bathina M, Lynch J, Koss B, Calabrese C et al. 2013. Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. Genes Dev 27:1351–64
    [Google Scholar]
  90. Warr MR, Acoca S, Liu Z, Germain M, Watson M et al. 2005. BH3-ligand regulates access of MCL-1 to its E3 ligase. FEBS Lett 579:5603–8
    [Google Scholar]
  91. Wilson WH, O'Connor OA, Czuczman MS, Lacasce AS, Gerecitano JF et al. 2010. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 11:1149–59
    [Google Scholar]
  92. Zantl N, Weirich G, Zall H, Seiffert BM, Fischer SF et al. 2007. Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistance. Oncogene 26:7038–48
    [Google Scholar]
  93. Zhang S, Zhang M, Jing Y, Yin X, Ma P et al. 2018. Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors. Nat. Commun. 9:215
    [Google Scholar]
  94. Zhong Q, Gao W, Du F, Wang X 2005. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 121:1085–95
    [Google Scholar]
/content/journals/10.1146/annurev-cancerbio-030419-033510
Loading
/content/journals/10.1146/annurev-cancerbio-030419-033510
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error